When a laboratory SOP is revised for lyophilised research vials, the named research compound is only one part of the record. Research Sciences FAQs state that all peptides contain trace amounts of mannitol, an excipient described as helping the vial not look empty and supporting stability during lyophilisation, solubility and protection in storage. A robust SOP should declare that excipient, link it to the batch documentation and train handlers to work within an in-vitro, research-use-only framework. These materials are not for human or veterinary use.
Why mannitol deserves a declared excipient line in the SOP
Laboratory SOPs often concentrate on the named research compound, but a declared excipient line is part of a complete materials record. Research Sciences states in its FAQs that all peptides contain trace amounts of mannitol. For a UK laboratory updating an SOP for a lyophilised research vial, that statement should trigger a controlled change: add mannitol to the excipient schedule, record the supplier declaration against the product and batch, and make clear that the vial is not to be treated as an excipient-free preparation. The shop describes mannitol’s role as helping the vial not look empty, supporting stability during lyophilisation, aiding solubility and protecting the material in storage. The SOP does not need to repeat marketing language, but it should capture those functions in a neutral formulation note so that analysts understand why the excipient is present.
For materials managers, the practical value is traceability. A declared excipient row links the vial label, product code and supplier statement to the batch CoA and the laboratory’s internal risk assessment. That row should sit alongside the usual fields for storage temperature, receipt date, container condition and assigned analyst. It should also prompt a documentation check: if the SOP says “formulation: research compound only” or omits excipients altogether, the reviewer should revise the wording rather than leave a gap. The purchaser remains responsible for lawful use, safe handling, storage, disposal and compliance with relevant UK requirements, including COSHH and laboratory safety standards. Declaring mannitol does not transfer that responsibility to the supplier, and it does not turn an RUO material into a medicine, medical device, injectable, treatment or food supplement.
Training should reinforce the point without overcomplicating it. Analysts do not need to memorise a formulation history; they need to know where the excipient is recorded, which batch document controls the vial, and why mannitol should not be omitted from the SOP merely because it is present in trace amounts. The access-controlled SOP should direct staff to the batch CoA and the supplier’s published excipient statement before the vial is assigned to an in-vitro study. This is also the right moment to repeat that the materials are not for human or veterinary use and must not be described or used for therapeutic, clinical or diagnostic purposes.
Documentation checks before the SOP is authorised
Before a revised SOP is authorised, the reviewer should assemble a small documentary pack: the product name, the label reference, the batch CoA, the supplier’s excipient statement and any internal risk assessment. Research Sciences uses a label reference format that combines the SKU code and expiry date, for example BPC10-03/27, and links that reference to the corresponding CoA. The SOP should tell staff to quote that reference when contacting the shop about documentation. This simple control prevents a common failure mode: a vial is booked into the laboratory under a generic product name while the batch-specific paperwork remains unopened.
The live site should be treated as the current source. For UK research groups that need to check the public catalogue before finalising the SOP, the Research Sciences pages indexed under Peptides uk provide a starting point for product listings and published documentation. The homepage publishes claims such as “≥99% Verified Purity” and lists “CoAs Janoshik Analytical Reports”, but those lines should be reconfirmed at the time of review and reconciled with the CoA that accompanies the exact batch. The CoA — not a headline figure — is the document to attach to the SOP change record. If the published wording changes, the SOP owner should note the review date and retain the version consulted.
Two further documentation points belong in the SOP because they affect batch identity. First, restocked products may carry the same Internal Test Reference (ITR) as earlier stock. An ITR links to associated sample testing reports; it does not confirm that separate deliveries come from the same production lot or that they have had separate independent testing. The SOP should therefore require batch-level checks rather than treating an ITR as a lot equivalence statement. Second, vial cap colours and other packaging may vary. Cap colour is not an indicator of identity, analytical quality or manufacturing origin, so it must not be used as a visual release criterion. Where the CoA provides excipient information, reconcile it with the supplier statement; where it does not, retain the published excipient declaration with the batch record and avoid inventing detail. The materials remain research-use-only and not for human or veterinary use.
Handling, storage and training controls for mannitol-containing vials
The presence of mannitol as a declared excipient should not change the basic handling controls already required for lyophilised research vials, but it should appear in the SOP’s materials description and training notes. Research Sciences’ handling guidance says vials should be allowed to reach room temperature before opening, opened in a clean environment, and only the amount required for the experiment should be removed. Lyophilised peptides should be stored at –20°C or below, sealed with desiccant, and protected from moisture, heat and light. Repeated freeze–thaw cycles should be avoided. Reconstituted peptides are less stable and should be stored at 2–8°C for short-term laboratory use. These are laboratory-workflow controls for in-vitro research, not instructions for human or veterinary use.
If the SOP contains a reconstitution step for an in-vitro assay, keep the language strictly analytical: record the diluent volume, the target concentration for the assay and the vial reference. The shop’s reconstitution calculator is described for laboratory research use only and must not be used for human or veterinary dosing. The SOP should state that reconstitution solutions are supplied separately where applicable and that the peptide and solvent are allowed to reach ambient temperature before reconstitution in a research setting. It should also identify who may perform the step, where the record is kept, and how unused material is handled. The excipient line for mannitol should be visible in the same record, so that a reviewer can see that the declared formulation has been considered rather than overlooked.
Training and audit controls should close the loop. Staff should be briefed that Research Sciences FAQs state all peptides contain trace amounts of mannitol; that the batch CoA and label reference are the controlling documents; that an ITR does not confirm same-lot status; and that cap colour is not an identity check. The materials manager should verify that the SOP’s excipient schedule, COSHH assessment and disposal instructions are consistent, and that the supplier’s current published wording has been reconfirmed. A signed training record is more useful than a general reminder because it shows that the analyst knows where mannitol is declared and which batch document to open. Throughout, the SOP should repeat that these materials are not for human or veterinary use and are supplied strictly for controlled laboratory and analytical research.
